JLE

European Journal of Dermatology

MENU

Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1®) after nivolumab discontinuation Volume 31, issue 1, January-February 2021

Figures


  • Figure 1
Authors
Department of Dermatology, Tenri Hospital, Tenri, Japan

Nivolumab is an anti-programmed cell death (PD)-1 antibody used to treat various types of cancers [1]. It has been associated with dermatological immune-related adverse events (irAEs) including Stevens-Johnson syndrome (SJS) [1-3]. Among the few follow-up studies of nivolumab-induced SJS after nivolumab discontinuation, recurrence of nivolumab-induced SJS due to other drugs has not been reported. The anti-tumour agent, tegafur/gimeracil/oteracil (TS-1®), has been reported to induce SJS and toxic [...]